TY - JOUR
T1 - High fatigue scores in patients with idiopathic inflammatory myopathies
T2 - a multigroup comparative study from the COVAD e-survey
AU - COVAD Study Group
AU - Grignaschi, Silvia
AU - Kim, Minchul
AU - Zanframundo, Giovanni
AU - Ravichandran, Naveen
AU - Lilleker, James B.
AU - Sen, Parikshit
AU - Joshi, Mrudula
AU - Agarwal, Vishwesh
AU - Kardes, Sinan
AU - Day, Jessica
AU - Makol, Ashima
AU - Milchert, Marcin
AU - Gheita, Tamer
AU - Salim, Babur
AU - Velikova, Tsvetelina
AU - Gracia-Ramos, Abraham Edgar
AU - Parodis, Ioannis
AU - Nikiphorou, Elena
AU - Chatterjee, Tulika
AU - Tan, Ai Lyn
AU - Saavedra, Miguel A.
AU - Shinjo, Samuel Katsuyuki
AU - Ziade, Nelly
AU - Knitza, Johannes
AU - Kuwana, Masataka
AU - Nune, Arvind
AU - Distler, Oliver
AU - Chinoy, Hector
AU - Cavagna, Lorenzo
AU - Agarwal, Vikas
AU - Aggarwal, Rohit
AU - Gupta, Latika
AU - Barman, Bhupen
AU - Singh, Yogesh Preet
AU - Ranjan, Rajiv
AU - Jain, Avinash
AU - Pandya, Sapan C.
AU - Pilania, Rakesh Kumar
AU - Sharma, Aman
AU - Manoj, M. Manesh
AU - Gupta, Vikas
AU - Kavadichanda, Chengappa G.
AU - Patro, Pradeepta Sekhar
AU - Ajmani, Sajal
AU - Phatak, Sanat
AU - Goswami, Rudra Prosad
AU - Chowdhury, Abhra Chandra
AU - Mathew, Ashish Jacob
AU - Shenoy, Padnamabha
AU - Asranna, Ajay
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/9
Y1 - 2023/9
N2 - Idiopathic inflammatory myopathies (IIMs) confer a significant risk of disability and poor quality of life, though fatigue, an important contributing factor, remains under-reported in these individuals. We aimed to compare and analyze differences in visual analog scale (VAS) scores (0–10 cm) for fatigue (VAS-F) in patients with IIMs, non-IIM systemic autoimmune diseases (SAIDs), and healthy controls (HCs). We performed a cross-sectional analysis of the data from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) international patient self-reported e-survey. The COVAD survey was circulated from December 2020 to August 2021, and details including demographics, COVID-19 history, vaccination details, SAID details, global health, and functional status were collected from adult patients having received at least one COVID-19 vaccine dose. Fatigue experienced 1 week prior to survey completion was assessed using a single-item 10 cm VAS. Determinants of fatigue were analyzed in regression models. Six thousand nine hundred and eighty-eight respondents (mean age 43.8 years, 72% female; 55% White) were included in the analysis. The overall VAS-F score was 3 (IQR 1–6). Patients with IIMs had similar fatigue scores (5, IQR 3–7) to non-IIM SAIDs [5 (IQR 2–7)], but higher compared to HCs (2, IQR 1–5; P < 0.001), regardless of disease activity. In adjusted analysis, higher VAS-F scores were seen in females (reference female; coefficient −0.17; 95%CI −0.21 to −13; P < 0.001) and Caucasians (reference Caucasians; coefficient −0.22; 95%CI −0.30 to −0.14; P < 0.001 for Asians and coefficient −0.08; 95%CI −0.13 to 0.30; P = 0.003 for Hispanics) in our cohort. Our study found that patients with IIMs exhibit considerable fatigue, similar to other SAIDs and higher than healthy individuals. Women and Caucasians experience greater fatigue scores, allowing identification of stratified groups for optimized multidisciplinary care and improve outcomes such as quality of life.
AB - Idiopathic inflammatory myopathies (IIMs) confer a significant risk of disability and poor quality of life, though fatigue, an important contributing factor, remains under-reported in these individuals. We aimed to compare and analyze differences in visual analog scale (VAS) scores (0–10 cm) for fatigue (VAS-F) in patients with IIMs, non-IIM systemic autoimmune diseases (SAIDs), and healthy controls (HCs). We performed a cross-sectional analysis of the data from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) international patient self-reported e-survey. The COVAD survey was circulated from December 2020 to August 2021, and details including demographics, COVID-19 history, vaccination details, SAID details, global health, and functional status were collected from adult patients having received at least one COVID-19 vaccine dose. Fatigue experienced 1 week prior to survey completion was assessed using a single-item 10 cm VAS. Determinants of fatigue were analyzed in regression models. Six thousand nine hundred and eighty-eight respondents (mean age 43.8 years, 72% female; 55% White) were included in the analysis. The overall VAS-F score was 3 (IQR 1–6). Patients with IIMs had similar fatigue scores (5, IQR 3–7) to non-IIM SAIDs [5 (IQR 2–7)], but higher compared to HCs (2, IQR 1–5; P < 0.001), regardless of disease activity. In adjusted analysis, higher VAS-F scores were seen in females (reference female; coefficient −0.17; 95%CI −0.21 to −13; P < 0.001) and Caucasians (reference Caucasians; coefficient −0.22; 95%CI −0.30 to −0.14; P < 0.001 for Asians and coefficient −0.08; 95%CI −0.13 to 0.30; P = 0.003 for Hispanics) in our cohort. Our study found that patients with IIMs exhibit considerable fatigue, similar to other SAIDs and higher than healthy individuals. Women and Caucasians experience greater fatigue scores, allowing identification of stratified groups for optimized multidisciplinary care and improve outcomes such as quality of life.
KW - Autoimmune diseases
KW - COVID-19
KW - Fatigue
KW - Myositis
KW - Surveys and questionnaires
UR - http://www.scopus.com/inward/record.url?scp=85163056433&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85163056433&partnerID=8YFLogxK
U2 - 10.1007/s00296-023-05344-z
DO - 10.1007/s00296-023-05344-z
M3 - Article
C2 - 37314497
AN - SCOPUS:85163056433
SN - 0172-8172
VL - 43
SP - 1637
EP - 1649
JO - Rheumatology International
JF - Rheumatology International
IS - 9
ER -